CO2021016552A2 - Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso - Google Patents
Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de usoInfo
- Publication number
- CO2021016552A2 CO2021016552A2 CONC2021/0016552A CO2021016552A CO2021016552A2 CO 2021016552 A2 CO2021016552 A2 CO 2021016552A2 CO 2021016552 A CO2021016552 A CO 2021016552A CO 2021016552 A2 CO2021016552 A2 CO 2021016552A2
- Authority
- CO
- Colombia
- Prior art keywords
- drug conjugates
- mcl
- methods
- antibody
- drug
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 4
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 4
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title abstract 3
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000562 conjugate Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se divulgan conjugados de anticuerpo anti-CD74-fármaco. Los conjugados de anticuerpo anti-CD74-fármaco comprenden una unidad de un fármaco inhibidor de Mcl-1 y un anticuerpo anti-CD74 o fragmento de unión al antígeno del mismo que se une a un antígeno blanco, por ejemplo, un antígeno expresado en un tumor u otra célula cancerosa. La divulgación también se relaciona con métodos y composiciones para usar en el tratamiento de cánceres mediante la administración de los conjugados de anticuerpo-fármaco provistos en la presente. Además, se divulgan conjugados de conector-fármaco que comprenden una unidad de un fármaco inhibidor de Mcl-1 y métodos para su elaboración.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962850098P | 2019-05-20 | 2019-05-20 | |
PCT/US2020/033602 WO2020236817A2 (en) | 2019-05-20 | 2020-05-19 | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021016552A2 true CO2021016552A2 (es) | 2022-04-08 |
Family
ID=70978687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0016552A CO2021016552A2 (es) | 2019-05-20 | 2021-12-06 | Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso |
Country Status (20)
Country | Link |
---|---|
US (2) | US20230092679A1 (es) |
EP (2) | EP3972649A2 (es) |
JP (2) | JP2022533400A (es) |
KR (2) | KR20220017931A (es) |
CN (2) | CN114728076A (es) |
AR (1) | AR122270A1 (es) |
AU (2) | AU2020279230A1 (es) |
BR (1) | BR112021023229A2 (es) |
CA (2) | CA3138058A1 (es) |
CL (1) | CL2021003042A1 (es) |
CO (1) | CO2021016552A2 (es) |
DO (1) | DOP2021000238A (es) |
IL (2) | IL288110A (es) |
JO (1) | JOP20210289A1 (es) |
MX (1) | MX2021014094A (es) |
PE (1) | PE20220218A1 (es) |
SG (1) | SG11202112056PA (es) |
TW (1) | TW202100184A (es) |
UY (1) | UY38700A (es) |
WO (2) | WO2020236817A2 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022093794A1 (en) | 2020-10-27 | 2022-05-05 | Elucida Oncology, Inc. | Methods of functionalizing nanoparticles |
AU2021386367A1 (en) | 2020-11-24 | 2023-06-22 | Les Laboratoires Servier | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
JP2023553808A (ja) * | 2020-11-24 | 2023-12-26 | ノバルティス アーゲー | Mcl-1阻害剤抗体-薬物コンジュゲートおよび使用方法 |
WO2022261301A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
AU2022290855A1 (en) | 2021-06-11 | 2023-12-07 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
WO2022266491A1 (en) * | 2021-06-18 | 2022-12-22 | University Of Maryland, Baltimore | Proteolysis targeting chimeras and polypharmacological agents targeting bcl-2, and methods of use thereof |
WO2023223097A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody drug conjugates |
WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
WO2023234426A1 (ja) * | 2022-06-03 | 2023-12-07 | Ube株式会社 | 抗体・複数薬物コンジュゲート |
WO2023234427A1 (ja) * | 2022-06-03 | 2023-12-07 | Ube株式会社 | 抗体・複数薬物コンジュゲート前駆体およびその合成中間体 |
WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
WO2024040073A1 (en) * | 2022-08-17 | 2024-02-22 | Lonza Sales Ag | Extracellular vesicle comprising a biologically active molecule and a cleavable linker |
WO2024040075A1 (en) * | 2022-08-17 | 2024-02-22 | Lonza Sales Ag | Extracellular vesicle comprising a biologically active molecule and a dual cleavable linker |
WO2024083161A1 (en) * | 2022-10-19 | 2024-04-25 | Multitude Therapeutics Inc. | Antibody-drug conjugate, preparation method and use thereof |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
WO1998056915A2 (en) | 1997-06-12 | 1998-12-17 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US7312318B2 (en) | 2002-03-01 | 2007-12-25 | Immunomedics, Inc. | Internalizing anti-CD74 antibodies and methods of use |
GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
DK1472275T3 (da) | 2002-02-05 | 2009-04-14 | Genentech Inc | Proteinoprensning |
NZ539395A (en) | 2002-11-07 | 2009-01-31 | Immunogen Inc | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
EP1577288B1 (en) | 2002-12-26 | 2014-07-23 | Eisai R&D Management Co., Ltd. | Selective estrogen receptor modulators |
TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
PE20110224A1 (es) | 2006-08-02 | 2011-04-05 | Novartis Ag | PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO |
EP2716643A1 (en) | 2008-08-22 | 2014-04-09 | Novartis AG | Pyrrolopyrimidine compounds and their uses |
MX2012000121A (es) | 2009-06-22 | 2012-03-07 | Medimmune Llc | Regiones fc modificadas para la conjugacion especifica del sitio. |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
EA022551B1 (ru) | 2010-06-10 | 2016-01-29 | Серагон Фармасьютикалс, Инк. | Модуляторы рецепторов эстрогена и их применение |
WO2011159769A2 (en) | 2010-06-17 | 2011-12-22 | Aragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
KR101972446B1 (ko) | 2011-05-27 | 2019-04-25 | 글락소 그룹 리미티드 | Bcma(cd269/tnfrsf17)결합 단백질 |
FR2986002B1 (fr) | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
ES2703540T3 (es) | 2012-06-04 | 2019-03-11 | Novartis Ag | Métodos de marcación específicos del sitio y moléculas producidas de este modo |
US20140069822A1 (en) | 2012-09-10 | 2014-03-13 | Antec Leyden B.V. | Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction |
AU2013350802B2 (en) | 2012-11-30 | 2016-07-14 | Novartis Ag | Methods for making conjugates from disulfide-containing proteins |
KR20150115000A (ko) | 2013-02-08 | 2015-10-13 | 아이알엠 엘엘씨 | 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위 |
WO2014124258A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
KR102279999B1 (ko) | 2013-02-19 | 2021-07-22 | 노파르티스 아게 | 선택적 에스트로겐 수용체 분해제로서의 벤조티오펜 유도체 및 그의 조성물 |
NZ710929A (en) * | 2013-03-15 | 2018-02-23 | Novartis Ag | Antibody drug conjugates |
FR3008975A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3015483B1 (fr) | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
SG11201606850QA (en) | 2014-03-12 | 2016-09-29 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
RU2016137150A (ru) | 2014-03-13 | 2018-04-18 | Ф. Хоффманн-Ля Рош Аг | Способы и композиции для модулирования мутантов эстрогеновых рецепторов |
JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
PE20170912A1 (es) * | 2014-11-14 | 2017-07-12 | Novartis Ag | Conjugados de anticuerpo-farmaco |
US20170182179A1 (en) | 2014-12-09 | 2017-06-29 | Abbvie Inc. | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors |
RU2020123953A (ru) | 2014-12-09 | 2020-09-18 | Эббви Инк. | Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и конъюгаты антитело-лекарственное средство, включающие их |
EP3230283A1 (en) | 2014-12-09 | 2017-10-18 | AbbVie Inc. | Bcl-xl inhibitory compounds and antibody drug conjugates including the same |
US20190194315A1 (en) | 2015-06-17 | 2019-06-27 | Novartis Ag | Antibody drug conjugates |
FR3037957B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037959B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037956B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037958B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP3165536A1 (en) * | 2015-11-09 | 2017-05-10 | Ludwig-Maximilians-Universität München | Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition |
FR3046792B1 (fr) | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US11306107B2 (en) | 2016-02-25 | 2022-04-19 | Amgen Inc. | Compounds that inhibit MCL-1 protein |
KR102388208B1 (ko) | 2016-04-22 | 2022-04-18 | 아스트라제네카 아베 | 암을 치료하기 위한 거대 환형 mcl1 억제제 |
AU2017277517A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-EGFR antibody drug conjugates |
US20190153107A1 (en) | 2016-06-08 | 2019-05-23 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
AU2017277914A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-CD98 antibodies and antibody drug conjugates |
CN116173232A (zh) | 2016-06-08 | 2023-05-30 | 艾伯维公司 | 抗cd98抗体及抗体药物偶联物 |
CA3027181A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
CN109563167A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
AU2017279550A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-B7-H3 antibodies and antibody drug conjugates |
US20200338209A1 (en) | 2016-06-08 | 2020-10-29 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
MX2018015272A (es) | 2016-06-08 | 2019-08-12 | Abbvie Inc | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. |
AU2017355402A1 (en) * | 2016-11-02 | 2019-05-30 | Health Research, Inc. | Combination treatment with antibody-drug conjugates and PARP inhibitors |
CA3043277A1 (en) | 2016-11-11 | 2018-05-17 | The Regents Of The University Of California | Anti-cd46 antibodies and methods of use |
WO2018098534A1 (en) * | 2016-12-02 | 2018-06-07 | Garvan Institute Of Medical Research | Methods of treating cancer and reagents thereof |
CN110461361A (zh) * | 2017-02-10 | 2019-11-15 | 蜻蜓治疗公司 | 结合bcma、nkg2d和cd16的蛋白 |
JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Mcl−1タンパク質を阻害する化合物 |
CN110312730A (zh) * | 2017-04-19 | 2019-10-08 | 四川科伦博泰生物医药股份有限公司 | 细胞毒素和偶联物、 其用途和制备方法 |
AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
EP3988555A1 (en) | 2017-08-15 | 2022-04-27 | AbbVie Inc. | Macrocyclic mcl-1 inhibitors and methods of use |
WO2019035899A1 (en) | 2017-08-15 | 2019-02-21 | Abbvie Inc. | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE |
EP3668502A4 (en) | 2017-08-15 | 2021-01-13 | AbbVie Inc. | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE |
US20190160089A1 (en) * | 2017-10-31 | 2019-05-30 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and cytarabine |
-
2020
- 2020-05-19 CA CA3138058A patent/CA3138058A1/en active Pending
- 2020-05-19 BR BR112021023229A patent/BR112021023229A2/pt unknown
- 2020-05-19 US US17/613,006 patent/US20230092679A1/en active Pending
- 2020-05-19 TW TW109116585A patent/TW202100184A/zh unknown
- 2020-05-19 JP JP2021568870A patent/JP2022533400A/ja active Pending
- 2020-05-19 MX MX2021014094A patent/MX2021014094A/es unknown
- 2020-05-19 WO PCT/US2020/033602 patent/WO2020236817A2/en active Application Filing
- 2020-05-19 PE PE2021001880A patent/PE20220218A1/es unknown
- 2020-05-19 KR KR1020217041091A patent/KR20220017931A/ko unknown
- 2020-05-19 JP JP2021568893A patent/JP2022532918A/ja active Pending
- 2020-05-19 CN CN202080043826.XA patent/CN114728076A/zh active Pending
- 2020-05-19 US US17/613,020 patent/US20230081720A1/en active Pending
- 2020-05-19 AU AU2020279230A patent/AU2020279230A1/en active Pending
- 2020-05-19 EP EP20730922.0A patent/EP3972649A2/en active Pending
- 2020-05-19 WO PCT/US2020/033615 patent/WO2020236825A2/en unknown
- 2020-05-19 CA CA3136088A patent/CA3136088A1/en active Pending
- 2020-05-19 AU AU2020279979A patent/AU2020279979A1/en active Pending
- 2020-05-19 EP EP20733328.7A patent/EP3972651A2/en active Pending
- 2020-05-19 KR KR1020217041613A patent/KR20220024106A/ko unknown
- 2020-05-19 JO JOP/2021/0289A patent/JOP20210289A1/ar unknown
- 2020-05-19 SG SG11202112056PA patent/SG11202112056PA/en unknown
- 2020-05-19 CN CN202080052440.5A patent/CN114728077A/zh active Pending
- 2020-05-19 AR ARP200101417A patent/AR122270A1/es unknown
- 2020-05-19 UY UY0001038700A patent/UY38700A/es unknown
-
2021
- 2021-11-14 IL IL288110A patent/IL288110A/en unknown
- 2021-11-15 IL IL288117A patent/IL288117A/en unknown
- 2021-11-17 CL CL2021003042A patent/CL2021003042A1/es unknown
- 2021-11-18 DO DO2021000238A patent/DOP2021000238A/es unknown
- 2021-12-06 CO CONC2021/0016552A patent/CO2021016552A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020236817A8 (en) | 2021-05-20 |
BR112021023229A2 (pt) | 2022-05-31 |
WO2020236817A2 (en) | 2020-11-26 |
WO2020236825A8 (en) | 2021-03-18 |
CL2021003042A1 (es) | 2022-07-15 |
CA3138058A1 (en) | 2020-11-26 |
CN114728076A (zh) | 2022-07-08 |
MX2021014094A (es) | 2022-02-11 |
JP2022532918A (ja) | 2022-07-20 |
IL288110A (en) | 2022-01-01 |
DOP2021000238A (es) | 2022-03-31 |
AU2020279979A1 (en) | 2021-11-25 |
US20230081720A1 (en) | 2023-03-16 |
PE20220218A1 (es) | 2022-02-02 |
CA3136088A1 (en) | 2020-11-26 |
SG11202112056PA (en) | 2021-12-30 |
EP3972649A2 (en) | 2022-03-30 |
AU2020279230A1 (en) | 2021-12-02 |
US20230092679A1 (en) | 2023-03-23 |
CN114728077A (zh) | 2022-07-08 |
KR20220017931A (ko) | 2022-02-14 |
AR122270A1 (es) | 2022-08-31 |
JP2022533400A (ja) | 2022-07-22 |
EP3972651A2 (en) | 2022-03-30 |
UY38700A (es) | 2020-12-31 |
WO2020236817A3 (en) | 2020-12-30 |
WO2020236825A2 (en) | 2020-11-26 |
IL288117A (en) | 2022-01-01 |
JOP20210289A1 (ar) | 2023-01-30 |
TW202100184A (zh) | 2021-01-01 |
WO2020236825A3 (en) | 2021-02-18 |
KR20220024106A (ko) | 2022-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021016552A2 (es) | Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso | |
DOP2019000280A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
CY1124791T1 (el) | Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων | |
CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
ECSP19044625A (es) | Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas | |
AR096015A1 (es) | Conjugados de fármacos con anticuerpos | |
AR080795A1 (es) | Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6) | |
AR104987A1 (es) | Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos | |
BR112021015036A2 (pt) | Tratamento para câncer com imunoconjugados do anticorpo ror1 | |
BR112019023909A8 (pt) | Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab | |
CO2022007924A2 (es) | Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso | |
AR120147A1 (es) | Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco | |
CL2021001593A1 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
ECSP21044421A (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
CO2022009696A2 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
CY1126032T1 (el) | Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap | |
AR114437A1 (es) | Conjugados para el direccionamiento hacia agregados y para la eliminación de los mismos | |
ECSP20082970A (es) | Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso | |
UY38265A (es) | Conjugados anticuerpo droga para ablación de células madre hematopoyéticas | |
CO2022001643A2 (es) | Anticuerpos anti-grp78 y método de uso de los mismos | |
BR112021022135A2 (pt) | Anticorpos biespecíficos contra chi3l1 e pd1 com efeitos citotóxicos mediados por célula t realçados sobre células de tumor | |
MX2020004074A (es) | Producto de combinacion para el tratamiento de cancer. | |
AR117446A1 (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
AR114222A1 (es) | Métodos de uso para células t con receptor de antígeno quimérico (car) | |
ECSP23045888A (es) | Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos |